当前位置: 首页 > 期刊 > 《中国当代医药》 > 2018年第4期
编号:13243152
重组组织型纤溶酶原激活物静脉溶栓治疗急性脑梗死的远期效果探讨(1)
http://www.100md.com 2018年2月5日 《中国当代医药》 2018年第4期
     [摘要]目的 探讨重组组织型纤溶酶原激活物(r-tPA)静脉溶栓治疗急性脑梗死的远期效果。方法 选取我院2015年1月~2017年1月收治的100例急性脑梗死患者作为研究对象,采取随机数字表法随机将患者分为两组,每组50例。所有患者均采取常规治疗,在常规治疗基础上,对照组加用阿司匹林肠溶片口服治疗,观察组加用r-tPA静脉溶栓治疗。比较两组的临床效果、预后情况、神经功能缺损评分、Barthel指数。结果 治疗后3个月,观察组的临床效果显著优于对照组,观察组的预后情况优于对照组(P<0.05)。治疗前,两组患者的神经功能缺损评分、Barthel指数比较差异无统计学意义(P>0.05);治疗后,两组的神经功能缺损评分均低于治疗前,Barthel指数均高于治疗前(P<0.05),观察组的神经功能缺损评分明显低于对照组,Barthel指数明显高于对照组(P<0.05)。结论 r-tPA静脉溶栓方案治疗急性脑梗死具有显著的临床效果,可促使其神经功能、日常生活能力有效恢复,有利于改善患者的远期预后。

    [关键词]急性脑梗死;静脉溶栓;重组组织型纤溶酶原激活物

    [中图分类号] R743.9 [文献标识码] A [文章编号] 1674-4721(2018)2(a)-0064-03

    [Abstract]Objective To explore the long-term effect of intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator (r-tPA) treating acute cerebral infarction.Methods From January 2015 to January 2017,100 patients with acute cerebral infarction admitted into our hospital were selected as research objects.Using a random number table method,they were divided into the two groups,and there were 50 cases in each group.All participants were provided with conventional therapy.On the basis of routine treatment,Aspirin Enteric-coated Tablets was added in the control group,while in the observation group,r-tPA was adopted.The clinical effect,prognosis,neurological deficit score,and Barthel index were compared between the two groups.Results After 3-month treatment,the clinical effect of the observation group was significantly better than that of the control group,and the prognosis in the observation group was better than that in the control group after 3-month treatment (P<0.05).Before treatment,there was no statistical difference in the score of neurological deficits or Barthel index between the two groups (P>0.05).After therapy,the score of neurological deficits in the two groups were both lower than those prior treatment (P<0.05),and Barthel index were significantly higher than those before treatment (P<0.05).The score of neurological impairment was lower and Barthel index was higher compared with those in the control group (P<0.05).Conclusion r-tPA intravenous thrombolysis is effective in the treatment of acute cerebral infarction,which can facilitate the recovery of neurological function as well as daily living ability,and helps improve the long-term prognosis of patients.

    [Key words]Acute cerebral infarction;Intravenous thrombolysis;Recombinant tissue-type plasminogen activator

    急性腦梗死属于神经内科常见疾病,具有较高的致残率、致死率,如患者未能得到及时治疗,容易引发严重后果,死亡风险较高,故临床上需对该疾病进行积极治疗[1]。溶栓治疗是急性脑梗死的一种治疗手段,重组组织型纤溶酶原激活物(recombinant tissue-type plasminogen activator,r-tPA)是急性脑梗死静脉溶栓治疗的主要药物,本研究目的在于探讨r-tPA静脉溶栓治疗急性脑梗死的效果,为此,以我院收治的100例急性脑梗死患者为对象展开研究,探讨r-tPA静脉溶栓治疗急性脑梗死的远期效果。, http://www.100md.com(钟传飘 方玲 蓝崧)
1 2 3下一页